KNE Kane Biotech Inc.

Kane Biotech Provides Update on Previously Announced Private Placement

Kane Biotech Provides Update on Previously Announced Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

WINNIPEG, Manitoba, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”), in accordance with the policies of the TSX Venture Exchange (“TSX-V”), wishes to provide an update on the status of the non-brokered private placement of the Company’s units (“Units” and each a “Unit”) at $0.14 per Unit for gross proceeds of up to $3,500,000 (the “Offering”), initially announced by the Company on December 4, 2019. Each Unit offered under the Offering consists of a common share of the Company (a “Common Share”) and one-half of one Common Share purchase warrant (each, a “Warrant”). Each whole Warrant is exercisable into a Common Share at $0.18 per Common Share for 24 months following issuance. As more particularly described in the press release dated December 4, 2019, the Company reserves to right to call the Warrants issued under the Offering at their exercise price of $0.18 per Warrant in the event that the Common Shares traded on the TSX-V have a closing price at or exceeding $0.25 per Common Share for five (5) consecutive trading days. 

The Company completed the first tranche of the Offering on December 19, 2019 by placing 17,918,137 Units for gross proceeds of $2,508,539.18. Due to continuing interest, the Company is pleased to confirm that it anticipates closing the second and final tranche of the Offering of up to 7,081,863 Units in the coming weeks.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (56 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, bluestem™, AloSera™, coactive+™ and Kane® are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE."

For more information, please visit , or contact:

Marc Edwards

Chief Executive Officer

Kane Biotech Inc.

+1 (514) 910-6991

 

Ray Dupuis

Chief Financial Officer

Kane Biotech Inc.

+1 (204) 298-2200

  

Stephen Kilmer

Investor Relations

Kane Biotech Inc.

+1 (646) 274-3580

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities laws. These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company's: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its Shares, volatility of the market price of its Shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at . The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.

EN
23/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kane Biotech Inc.

 PRESS RELEASE

Kane Biotech Provides Further Corporate Update

Kane Biotech Provides Further Corporate Update WINNIPEG, Manitoba, June 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) provides updates on its reorganizational phase. The Company has terminated its exclusive distribution agreement with ProgenaCare Global LLC (“ProgenaCare”) dated April 18, 2023 due to various material breaches by ProgenaCare of the agreement. Activities to resecure distribution for its products in the United States are underway. The Company recently received a notice of default from Prairies Economic Development ...

 PRESS RELEASE

Kane Biotech Announces First Quarter 2025 Financial Results

Kane Biotech Announces First Quarter 2025 Financial Results WINNIPEG, Manitoba, May 29, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its first quarter 2025 financial results. First Quarter 2025 Financial Highlights (Comparatives Exclude Discontinued STEM Animal Health “STEM” Operations): Total revenue for the three months ended March 31, 2025 was $412,513 compared to $51,886 in the three months ended March 31, 2024. Revenue in the current quarter consists primarily of contract animal health manufacturing revenue for...

 PRESS RELEASE

Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Res...

Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change WINNIPEG, Manitoba, April 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announced its fourth quarter and full year 2024 financial results. Fourth Quarter 2024 Financial Highlights (Comparatives Exclude Discontinued STEM Animal Health “STEM” Operations): Total revenue for the three months ended December 31,2024 was $125,859 compared to $57,788 in the three months ended December 31, 2023. F...

 PRESS RELEASE

Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acn...

Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial Kane to work with the University of Miami to study DispersinB® Acne Cleanser in mild to moderate Acne Vulgaris WINNIPEG, Manitoba, March 13, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) ("Kane Biotech" or "Kane") announces today that it has received approval from the Internal Review Board (“IRB”) of the University of Miami Health System (“UHealth”) to commence a clinical study of Kane’s prototype DispersinB® Acne Cleanser for the treatment of mild to moderate cases of Acne Vulgaris. The ...

 PRESS RELEASE

Kane Biotech Announces Canadian Distribution Agreement With Best Buy M...

Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel Strategic Partnership Expands Access to Innovative Wound Care Solution Across Canada WINNIPEG, Manitoba, March 11, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (“Kane Biotech”) announces that it has concluded a three-year distribution agreement with Best Buy Medical Canada for its revyve™ Antimicrobial Wound Gel Product line. In November 2024, Kane Biotech received Health Canada approval for its revyve™ Antimicrobial Wound Gel, marking a significant...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch